GenSight Biologics (SIGHT.PA) H1 2026 net loss widens to €10.3 mln, going-concern warning

GenSight Biologics said its H1 2026 net loss widened to €10.3 mln versus a steady loss per share of €0.05 and warned of material uncertainty over going concern without additional funding.